Brian S. Bronk

Discovery of 4-(5-Methyloxazolo[4,5-<i>b</i>]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a Novel α7 Nicotinic Acetylcholine Receptor Agonist for the Treatment of Cognitive Disorders in Schizophrenia: Synthesis, SAR Development, and in Vivo Efficacy in Cognition Models

Christopher J. O’Donnell, Bruce N. Rogers, Brian S. Bronk et al. · Journal of Medicinal Chemistry · 2009 · 73 citations · Full text

Palladium(0) catalysis in hydrostannation of carbon-carbon triple bonds

John C. Cochran, Brian S. Bronk, Kathleen M. Terrence et al. · Tetrahedron Letters · 1990 · 57 citations

Carbon-carbon Triple Bonds, Organometallic Catalysis, Catalysis +3

Optimization of a Natural Product-Based Class of γ-Secretase Modulators

Jed L. Hubbs, Nathan O. Fuller, Wesley Austin et al. · Journal of Medicinal Chemistry · 2012 · 46 citations

Triterpene-based γ-Secretase Modulators, Molecular Pharmacology, Protein Secretion +14

Synthesis and Activity of a Novel Class of Tribasic Macrocyclic Antibiotics: The Triamilides

Michael A. Letavic, Brian S. Bronk, Camilla D. Bertsche et al. · Bioorganic & Medicinal Chemistry Letters · 2002 · 45 citations

Tribasic Macrocyclic Antibiotics, Organic Chemistry, Novel Class +5

Discovery of a potent, selective and orally active canine COX-2 inhibitor, 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl-pyridine

Jin Li, Kristin M. Lundy DeMello, Henry S. Cheng et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 38 citations · Full text

Medicinal Chemistry, Pharmaceutical Science, Medicine +7